These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 17682185)

  • 21. Sequential or concurrent administration of trastuzumab in early breast cancer? Too early to judge.
    Azim HA; de Azambuja E; Paesmans M; Piccart-Gebhart MJ
    J Clin Oncol; 2010 Jul; 28(21):e353-4. PubMed ID: 20406919
    [No Abstract]   [Full Text] [Related]  

  • 22. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
    Altundag K; Baptista MZ
    Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
    [No Abstract]   [Full Text] [Related]  

  • 23. [Adjuvant treatment of breast cancer in 2004. A review of the 8th consensus conference of St. Gallen and new study results].
    Kahlert S; von Koch F; Ditsch N; Untch M
    Gynakol Geburtshilfliche Rundsch; 2004 Apr; 44(2):102-12. PubMed ID: 15073439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer: review of platinum-based cooperative group trials.
    Pegram M
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S2-9. PubMed ID: 19780241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Adjuvant chemotherapy in primary carcinoma of the breast].
    Harbeck N
    Zentralbl Gynakol; 2003 Sep; 125(9):322-6. PubMed ID: 14569511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab in breast cancer.
    Gounaris IG
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470950
    [No Abstract]   [Full Text] [Related]  

  • 27. Ongoing and planned adjuvant trials with trastuzumab.
    Perez EA; Hortobagyi GN
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100. PubMed ID: 11236024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM).
    Colomer R; Viñas G; Beltran M; Izquierdo A; Lluch A; Llombart-Cussac A; Alba E; Munárriz B; Martín M;
    J Clin Oncol; 2004 Mar; 22(5):961-2. PubMed ID: 14990656
    [No Abstract]   [Full Text] [Related]  

  • 29. Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors.
    Altundag K; Altundag O; Islam R; Gundeslioglu O
    Med Hypotheses; 2006; 66(5):1045-6. PubMed ID: 16043302
    [No Abstract]   [Full Text] [Related]  

  • 30. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Magné N; Chargari C
    Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
    [No Abstract]   [Full Text] [Related]  

  • 31. Lapatinib in breast cancer: clinical experiences and future perspectives.
    Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight.
    Lin NU; Winer EP
    J Clin Oncol; 2011 Jan; 29(3):251-3. PubMed ID: 21149664
    [No Abstract]   [Full Text] [Related]  

  • 34. New options in the prevention and treatment of breast carcinoma.
    Galleshaw J
    J Med Assoc Ga; 2003; 92(1):19-22. PubMed ID: 12743901
    [No Abstract]   [Full Text] [Related]  

  • 35. [Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice].
    Campone M; Fumoleau P
    Bull Cancer; 2002 Mar; 89(3):275-82. PubMed ID: 11940467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.
    Metzger-Filho O; Vora T; Awada A
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S31-9. PubMed ID: 20374028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant chemotherapy for the treatment of HER2-positive early breast cancer.
    Clavarezza M; Venturini M
    Oncology; 2009; 77 Suppl 1():14-7. PubMed ID: 20130427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current perspective - trastuzumab.
    Hall PS; Cameron DA
    Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab plus chemotherapy: convincing survival benefit or not?
    Vogel CL; Tan-Chiu E
    J Clin Oncol; 2005 Jul; 23(19):4247-50. PubMed ID: 15911863
    [No Abstract]   [Full Text] [Related]  

  • 40. Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma.
    Puglisi F; de Azambuja E; de Castro G; Demonty G
    J Clin Oncol; 2005 Sep; 23(27):6803-4; author reply 6804-5. PubMed ID: 16170195
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.